

Michael Bhm

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3820666/michael-bohm-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

418 papers	47,892 citations	93 h-index	215 g-index
452 ext. papers	62,482 ext. citations	8.7 avg, IF	7.09 L-index

#	Paper	IF	Citations
418	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 12	8.7	0
417	Sodium-Glukose-Transporter2(SGLT2)-Hemmer bei Herzinsuffizienz. <i>Kardiologie</i> , 2022 , 16, 46-52	0.6	0
416	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <i>European Journal of Heart Failure</i> , 2022 , 24, 1-131	12.3	50
415	Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD.. <i>Circulation Research</i> , 2022 , CIRCRESAHA121320104	15.7	0
414	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	3
413	Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study.. <i>Integrated Blood Pressure Control</i> , 2022 , 15, 11-21	3.5	2
412	Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study.. <i>Lancet Rheumatology</i> , 2022 ,	14.2	4
411	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium.. <i>Circulation</i> , 2022 , 145, 847-863	16.7	3
410	Pulmonary artery sensor system pressure monitoring to improve heart failure outcomes (PASSPORT-HF): rationale and design of the PASSPORT-HF multicenter randomized clinical trial.. <i>Clinical Research in Cardiology</i> , 2022 , 1	6.1	2
409	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF.. <i>Circulation: Heart Failure</i> , 2022 , CIRCHEARTFAILURE121008970	7.6	0
408	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.. <i>Lancet, The</i> , 2022 , 399, 1401-1410	40	11
407	Ischemic Stroke-A Scientometric Analysis.. <i>Frontiers in Neurology</i> , 2022 , 13, 893121	4.1	
406	Management strategies in heart failure with preserved ejection fraction.. <i>Herz</i> , 2022 , 1	2.6	2
405	Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial.. <i>Hypertension</i> , 2022 , 101161HYPERENSIONAHA12118641	8.5	1
404	Herz und Niere. <i>Springer Reference Medizin</i> , 2022 , 1-15	0	
403	Time is prognosis in heart failure: time-to-treatment initiation as a modifiable risk factor. <i>ESC Heart Failure</i> , 2021 , 8, 4444	3.7	4
402	Less loop diuretic use in patients on sacubitril/valsartan undergoing remote pulmonary artery pressure monitoring. <i>ESC Heart Failure</i> , 2021 ,	3.7	3

401	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	5
400	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2021 ,	16.7	12
399	Device-related risk of atrial fibrillation after closure of patent foramen ovale: a systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	1
398	Sex Differences in Cardiovascular Research: A Scientometric Analysis. <i>Journal of the American Heart Association</i> , 2021 , e021522	6	2
397	Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2021 , 23, 1960-1970	12.3	4
396	Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2021 , 1	0.8	
395	Loss of Mitochondrial Ca Uniporter Limits Inotropic Reserve and Provides Trigger and Substrate for Arrhythmias in Barth Syndrome Cardiomyopathy. <i>Circulation</i> , 2021 , 144, 1694-1713	16.7	3
394	Drug Layering in Heart Failure: Phenotype-Guided Initiation. <i>JACC: Heart Failure</i> , 2021 , 9, 775-783	7.9	4
393	Comparison of Long-Term Outcomes for Responders Versus Non-Responders Following Renal Denervation in Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2021 , 10, e022429	6	3
392	Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. <i>Journal of Human Hypertension</i> , 2021 , 35, 903-911	2.6	7
391	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021 , 42, 1742-1756	9.5	20
390	The current status of renal denervation for the treatment of arterial hypertension. <i>Progress in Cardiovascular Diseases</i> , 2021 , 65, 76-83	8.5	5
389	Kardiovaskuläre Forschung in Deutschland 2020 Eine szientometrische Analyse. <i>Kardiologie</i> , 2021 , 15, 160-167	0.6	
388	Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. <i>Circulation</i> , 2021 , 143, 1157-1172	16.7	130
387	Inducibility of atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021 , 44, 667-676	1.6	2
386	Therapie bei Diabetes und Niereninsuffizienz. <i>Kardiologie</i> , 2021 , 15, 133-139	0.6	
385	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. <i>European Journal of Heart Failure</i> , 2021 , 23, 352-380	12.3	143
384	Arterielle Hypertonie Was war 2020 wichtig?. <i>Kardiologie</i> , 2021 , 15, 127-132	0.6	0

383	The significance of left ventricular ejection time in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021 , 23, 541-551	12.3	2
382	Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021 , 14, e007421	7.6	7
381	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , 2021 , 44, 665-674	3.3	1
380	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021 , 16, e1496-e1502	3.1	5
379	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021 ,	3.3	84
378	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. <i>JACC: Heart Failure</i> , 2021 , 9, 254-264	7.9	23
377	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 872-881	12.3	41
376	Timely and individualized heart failure management: need for implementation into the new guidelines. <i>Clinical Research in Cardiology</i> , 2021 , 110, 1150-1158	6.1	3
375	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021 , 143, 1962-1972	16.7	13
374	Changes in quality of life, depression, general anxiety, and heart-focused anxiety after defibrillator implantation. <i>ESC Heart Failure</i> , 2021 , 8, 2502-2512	3.7	4
373	COVID-19 and the heart: insights from the National Societies of Cardiology Journals. <i>European Heart Journal</i> , 2021 , 42, 4003-4005	9.5	0
372	Markers of cholesterol synthesis to cholesterol absorption across the spectrum of non-dialysis CKD: An observational study. <i>Pharmacology Research and Perspectives</i> , 2021 , 9, e00801	3.1	1
371	Effects of face masks on performance and cardiorespiratory response in well-trained athletes. <i>Clinical Research in Cardiology</i> , 2021 , 1	6.1	7
370	Effects of selective heart rate reduction with ivabradine on LV function and central hemodynamics in patients with chronic coronary syndrome. <i>IJC Heart and Vasculature</i> , 2021 , 34, 100757	2.4	0
369	Renal denervation in patients with versus without chronic kidney disease: results from the global SYMPPLICITY Registry with follow-up data of 3 years. <i>Nephrology Dialysis Transplantation</i> , 2021 ,	4.3	6
368	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2909-2919	15.1	21
367	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , 2021 , 149, 27-35	3	3
366	Expert opinion paper on cardiac imaging after ischemic stroke. <i>Clinical Research in Cardiology</i> , 2021 , 110, 938-958	6.1	1

365	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. <i>Lancet, The</i> , 2021 , 397, 2476-2486	4 ⁰	47
364	Blood pressure and renal denervation with ultrasound: another step forward. <i>Lancet, The</i> , 2021 , 397, 2441-2443	4 ⁰	
363	Myopathic Cardiac Genotypes Increase Risk for Myocarditis. <i>JACC Basic To Translational Science</i> , 2021 , 6, 584-592	8.7	6
362	The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021 , 8, 3566-3576	3.7	3
361	European Society of Hypertension position paper on renal denervation 2021. <i>Journal of Hypertension</i> , 2021 , 39, 1733-1741	1.9	21
360	Kriterien der Deutschen Gesellschaft für Kardiologie [Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL / Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von Remote-Monitoring-Systemen (RDS) [Abstract]. <i>Kardiologie</i> , 2021 , 15, 143-150	0.6	0
359	Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial. <i>Clinical Research in Cardiology</i> , 2021 , 110, 725-731	6.1	7
358	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. <i>Circulation</i> , 2021 , 143, 298-309	16.7	69
357	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 105-116	59.2	164
356	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , 2021 , 143, 337-349	16.7	80
355	Remote Monitoring With Appropriate Reaction to Alerts Was Associated With Improved Outcomes in Chronic Heart Failure: Results From the OptiLink HF Study. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e008693	6.4	1
354	Repeated exposure to transient obstructive sleep apnea-related conditions causes an atrial fibrillation substrate in a chronic rat model. <i>Heart Rhythm</i> , 2021 , 18, 455-464	6.7	7
353	Valvular heart disease in patients with chronic kidney disease. <i>Herz</i> , 2021 , 46, 228-233	2.6	3
352	Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. <i>Journal of Hypertension</i> , 2021 , 39, 1602-1610	1.9	0
351	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. <i>ESC Heart Failure</i> , 2021 , 8, 861-871	3.7	8
350	Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. <i>Journal of Hypertension</i> , 2021 , 39, 766-774	1.9	2
349	Drug adherence and psychosocial characteristics of patients presenting with hypertensive urgency at the emergency department. <i>Journal of Hypertension</i> , 2021 , 39, 1697-1704	1.9	1
348	Determinants of HIV-1 Late Presentation in Patients Followed in Europe. <i>Pathogens</i> , 2021 , 10,	4.5	5

347	Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1493-1503	2.6	2
346	Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. <i>Atherosclerosis</i> , 2021 , 330, 8-13	3.1	1
345	Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2814-2818	6.7	4
344	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. <i>New England Journal of Medicine</i> , 2021 , 385, 1451-1461	59.2	358
343	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	9.5	875
342	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1028-1038	15.1	5
341	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021 , 23, 100818	1.8	1
340	Neue Therapiekonzepte der HfREF. <i>Kardiologie Up2date</i> , 2021 , 17, 267-279	0	
339	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1337-1348	15.1	8
338	Interleukin-1 β is a Central Regulator of Leukocyte-Endothelial Adhesion in Myocardial Infarction and in Chronic Kidney Disease. <i>Circulation</i> , 2021 , 144, 893-908	16.7	8
337	Arterial hypertension - Clinical trials update 2021. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021 ,	4.5	1
336	Innovationen in der medikamentösen Therapie der Herzinsuffizienz. <i>CardioVasc</i> , 2021 , 21, 39-46	0	
335	Blood pressure lowering with alcohol-mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 98, E832-E838	2.7	
334	Differences in management of telemedicine alerts on weekdays and public holidays: Results from the OptiLink heart failure trial. <i>Journal of Telemedicine and Telecare</i> , 2021 , 1357633X211039398	6.8	
333	Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study. <i>Cardiovascular Diabetology</i> , 2021 , 20, 6	8.7	13
332	Hypertension trials update. <i>Journal of Human Hypertension</i> , 2021 , 35, 398-409	2.6	4
331	Accuracy of pulse rate derived from 24-h ambulatory blood pressure monitoring compared with heart rate from 24-h Holter-ECG. <i>Journal of Hypertension</i> , 2020 , 38, 2387-2392	1.9	4
330	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , 2020 , 41, 2848-2859	9.5	11

329	Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1446-1459	6.1	34
328	Renal Denervation in High-Risk Patients With Hypertension. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2879-2888	15.1	41
327	Development, establishment and validation of in vitro and ex vivo assays of vascular calcification. <i>Biochemical and Biophysical Research Communications</i> , 2020 , 530, 462-470	3.4	6
326	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1644-1656	15.1	23
325	Wissenschaftslandschaft Deutschland. <i>Kardiologe</i> , 2020 , 14, 113-123	0.6	2
324	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1353-1368	27.4	155
323	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , 2020 , 395, 1444-1451	4.0	166
322	Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). <i>European Journal of Heart Failure</i> , 2020 , 22, 1891-1901	12.3	52
321	Adherence to Antihypertensive Drugs Assessed by Hyphenated High-Resolution Mass Spectrometry Analysis of Oral Fluids. <i>Journal of the American Heart Association</i> , 2020 , 9, e014180	6	5
320	Long-term outcome after thrombus aspiration in non-ST-elevation myocardial infarction: results from the TATORT-NSTEMI trial : Thrombus aspiration in acute myocardial infarction. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1223-1231	6.1	3
319	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHEUS trial. <i>European Heart Journal</i> , 2020 , 41, 1673-1683	9.5	17
318	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 471-484	5	30
317	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020 , 109, 289-302	6.1	15
316	Survival After Coronary Revascularization With Paclitaxel-Coated Balloons. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1017-1028	15.1	35
315	Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM. <i>JACC: Case Reports</i> , 2020 , 2, 384-388	1.2	
314	Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1079-1098	6.1	41
313	Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2020 , 38, 783-790	1.9	14
312	Confounding Factors in Renal Denervation Trials: Revisiting Old and Identifying New Challenges in Trial Design of Device Therapies for Hypertension. <i>Hypertension</i> , 2020 , 76, 1410-1417	8.5	18

311	"Dear Doctor" Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. <i>Deutsches Arzteblatt International</i> , 2020 , 117, 687-688	2.5	1
310	Research Output and International Cooperation Among Countries During the COVID-19 Pandemic: Scientometric Analysis. <i>Journal of Medical Internet Research</i> , 2020 , 22, e24514	7.6	4
309	Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. <i>EuroIntervention</i> , 2020 , 16, 89-96	3.1	24
308	Optimization of Heart Failure Treatment by Heart Rate Reduction. <i>International Journal of Heart Failure</i> , 2020 , 2, 1	1.3	0
307	Association of clinic and ambulatory heart rate parameters with mortality in hypertension. <i>Journal of Hypertension</i> , 2020 , 38, 2416-2426	1.9	6
306	Contemporary scientometric analyses using a novel web application: the science performance evaluation (SciPE) approach. <i>Clinical Research in Cardiology</i> , 2020 , 109, 810-818	6.1	12
305	Time-updated resting heart rate predicts mortality in patients with COPD. <i>Clinical Research in Cardiology</i> , 2020 , 109, 776-786	6.1	7
304	Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. <i>Nature Immunology</i> , 2020 , 21, 30-41	19.1	78
303	Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial. <i>Journal of Hypertension</i> , 2020 , 38, 420-425	1.9	5
302	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020 , 22, 528-538	12.3	16
301	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 126-135	12.3	30
300	One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. <i>Clinical Research in Cardiology</i> , 2020 , 109, 845-856	6.1	11
299	Cathepsin A contributes to left ventricular remodeling by degrading extracellular superoxide dismutase in mice. <i>Journal of Biological Chemistry</i> , 2020 , 295, 12605-12617	5.4	1
298	Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2020 , 41, 2556-2569	9.5	7
297	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020 , 142, 1040-1054	16.7	52
296	A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model. <i>Clinical Research in Cardiology</i> , 2020 , 1	6.1	5
295	J-curve revisited. <i>European Heart Journal</i> , 2020 , 41, 4283	9.5	
294	Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure. <i>European Heart Journal</i> , 2020 , 41, 4600	9.5	1

293	Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19. <i>Clinical Research in Cardiology</i> , 2020 , 109, 1500-1506	6.1	23
292	The impact of pharmacist/physician care on quality of life in elderly heart failure patients: results of the PHARM-CHF randomized controlled trial. <i>ESC Heart Failure</i> , 2020 , 7, 3310	3.7	5
291	Research in Atrial Fibrillation: A Scientometric Analysis Using the Novel Web Application SciPE. <i>JACC: Clinical Electrophysiology</i> , 2020 , 6, 1008-1018	4.6	8
290	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2020 , 22, 2147-2156	12.3	41
289	Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. <i>Journal of Hypertension</i> , 2020 , 38, 1829-1840	1.9	10
288	MicroRNA-mediated vascular intercellular communication is altered in chronic kidney disease. <i>Cardiovascular Research</i> , 2020 ,	9.9	11
287	Development and implementation of blood pressure screening and referral guidelines for German community pharmacists. <i>Journal of Clinical Hypertension</i> , 2020 , 22, 1807-1816	2.3	2
286	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. <i>Circulation</i> , 2020 , 142, 1623-1632	16.7	20
285	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020 , 41, 3787-3797	9.5	35
284	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1413-1424	59.2	1099
283	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020 , 41, 3402-3418	9.5	40
282	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , 2020 , 41, 231-238	9.5	16
281	The Current Status of Devices for the Treatment of Resistant Hypertension. <i>American Journal of Hypertension</i> , 2020 , 33, 10-18	2.3	1
280	Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension. <i>Clinical Research in Cardiology</i> , 2020 , 109, 581-588	6.1	6
279	Letter on PPharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trialP reply. <i>European Journal of Heart Failure</i> , 2020 , 22, 565-566	12.3	1
278	Device-based therapies for arterial hypertension. <i>Nature Reviews Cardiology</i> , 2020 , 17, 614-628	14.8	35
277	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019 , 21, 1469-1472	12.3	9
276	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2019 , 381, 1995-2008	59.2	2021

275	Irregular pacing of ventricular cardiomyocytes induces pro-fibrotic signalling involving paracrine effects of transforming growth factor beta and connective tissue growth factor. <i>European Journal of Heart Failure</i> , 2019 , 21, 482-491	12.3	10
274	Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1012-1021	12.3	33
273	Arteriovenous Fistula, Blood Pressure, and Shunt Flow: A Thin Line That Separates Beneficial From Detrimental Effects. <i>American Journal of Hypertension</i> , 2019 , 32, 935-937	2.3	
272	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019 , 21, 665-675	12.3	145
271	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control Following Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. <i>Circulation</i> , 2019 ,	16.7	58
270	Rationale and design of the DIGIT-HF trial (DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure): a randomized, double-blind, placebo-controlled study. <i>European Journal of Heart Failure</i> , 2019 , 21, 676-684	12.3	21
269	Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , 2019 , 40, 3474-3482	9.5	95
268	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , 2019 , 40, 2032-2043	9.5	23
267	PhysiciansPguideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 921-929	12.3	53
266	Effects of Arteriovenous Fistula on Blood Pressure in Patients With End-Stage Renal Disease: A Systematic Meta-Analysis. <i>Journal of the American Heart Association</i> , 2019 , 8, e011183	6	19
265	Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction. <i>Clinical Research in Cardiology</i> , 2019 , 108, 290-297	6.1	17
264	Effects of Serelaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019 , 381, 716-726	59.2	92
263	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1270-1278	12.3	73
262	Cathepsin A Mediates Ventricular RemoteRemodeling and Atrial Cardiomyopathy in Rats With VentricularIschemia/Reperfusion. <i>JACC Basic To Translational Science</i> , 2019 , 4, 332-344	8.7	7
261	Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy. <i>Hypertension</i> , 2019 , HYPERTENSIONAHA11913081	8.5	12
260	Renal Denervation for TreatingHypertension: Current Scientific and Clinical Evidence. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1095-1105	5	36
259	Renal Denervation: Is It Ready for Prime Time?. <i>Current Cardiology Reports</i> , 2019 , 21, 80	4.2	5
258	Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1279-1287	12.3	133

257	Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m. <i>ESC Heart Failure</i> , 2019 , 6, 1199-1207	3.7	7
256	Physiological monitoring in the complex multimorbid heart failure patient - Conclusions. <i>European Heart Journal Supplements</i> , 2019 , 21, M68-M71	1.5	1
255	Effects of heart rate reduction with ivabradine on vascular stiffness and endothelial function in chronic stable coronary artery disease. <i>Journal of Hypertension</i> , 2019 , 37, 1023-1031	1.9	14
254	Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2893-2904	15.1	17
253	Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension: 12-month results from the ACHIEVE study. <i>Journal of Hypertension</i> , 2019 , 37, 1906-1912	1.9	5
252	Differential effects of endurance, interval, and resistance training on telomerase activity and telomere length in a randomized, controlled study. <i>European Heart Journal</i> , 2019 , 40, 34-46	9.5	85
251	Role of autonomic nervous system in atrial fibrillation. <i>International Journal of Cardiology</i> , 2019 , 287, 181-188	3.2	41
250	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019 , 40, 743-751	9.5	44
249	Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis. <i>Clinical Research in Cardiology</i> , 2019 , 108, 574-576	6.1	3
248	Association of medication adherence and depression with the control of low-density lipoprotein cholesterol and blood pressure in patients at high cardiovascular risk. <i>Patient Preference and Adherence</i> , 2019 , 13, 9-19	2.4	11
247	Interaction of systolic blood pressure and resting heart rate with clinical outcomes in takotsubo syndrome: insights from the International Takotsubo Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 1021-1030	12.3	23
246	Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency. <i>Cardiovascular Revascularization Medicine</i> , 2018 , 19, 845-851	1.6	8
245	Real-time left ventricular pressure-volume loops during percutaneous central arteriovenous anastomosis. <i>European Heart Journal</i> , 2018 , 39, 2330-2331	9.5	8
244	Vena Cava Compression Syndrome in Obesity is Reversed by Bariatric Surgery. <i>American Journal of Medicine</i> , 2018 , 131, e291-e292	2.4	1
243	Modulation of renal sympathetic innervation: recent insights beyond blood pressure control. <i>Clinical Autonomic Research</i> , 2018 , 28, 375-384	4.3	13
242	The association between different features of sleep-disordered breathing and blood pressure: A cross-sectional study. <i>Journal of Clinical Hypertension</i> , 2018 , 20, 575-581	2.3	10
241	The new SFB/TRR219 Research Centre. <i>European Heart Journal</i> , 2018 , 39, 975-977	9.5	5
240	Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial. <i>Clinical Research in Cardiology</i> , 2018 , 107, 642-652	6.1	13

239	Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. <i>European Heart Journal</i> , 2018 , 39, 26-35	9.5	245
238	Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT. <i>European Journal of Heart Failure</i> , 2018 , 20, 373-381	12.3	24
237	Sympathoadrenergic suppression improves heart function by upregulating the ratio of sRAGE/RAGE in hypertension with metabolic syndrome. <i>Journal of Molecular and Cellular Cardiology</i> , 2018 , 122, 34-46	5.8	6
236	Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>European Heart Journal</i> , 2018 , 39, 3105-3114	9.5	54
235	Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. <i>European Journal of Heart Failure</i> , 2018 , 20, 1315-1322	12.3	62
234	Renal artery anatomy assessed by quantitative analysis of selective renal angiography in 1,000 patients with hypertension. <i>EuroIntervention</i> , 2018 , 14, 121-128	3.1	10
233	Marathon running increases circulating endothelial- and thrombocyte-derived microparticles. <i>European Journal of Preventive Cardiology</i> , 2018 , 25, 317-324	3.9	18
232	Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model. <i>Journal of Hypertension</i> , 2018 , 36, 2453-2459	1.9	6
231	Twenty-Four-Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial. <i>Circulation</i> , 2018 , 138, 1602-1604	16.7	28
230	High blood pressure in coronary artery disease: when to start treating and what to target?. <i>European Heart Journal</i> , 2018 , 39, 3864-3866	9.5	2
229	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018 , 391, 2346-2355	40	358
228	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. <i>Lancet, The</i> , 2018 , 391, 2335-2345	40	301
227	Safety and feasibility of pulmonary artery pressure-guided heart failure therapy: rationale and design of the prospective CardioMEMS Monitoring Study for Heart Failure (MEMS-HF). <i>Clinical Research in Cardiology</i> , 2018 , 107, 991-1002	6.1	20
226	PHARMacy-based interdisciplinary program for patients with Chronic Heart Failure (PHARM-CHF): rationale and design of a randomized controlled trial, and results of the pilot study. <i>European Journal of Heart Failure</i> , 2018 , 20, 1350-1359	12.3	15
225	Hypertension: history and development of established and novel treatments. <i>Clinical Research in Cardiology</i> , 2018 , 107, 16-29	6.1	15
224	Thrombus aspiration in non-ST-elevation myocardial infarction - 12-month clinical outcome of the randomised TATORT-NSTEMI trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017 , 6, 10-17	4.3	12
223	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , 2017 , 241, 373-378	3.2	19
222	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 1495-1503	12.3	111

221	Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 2885-2896	15.1	132
220	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 552-562	12.3	19
219	Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPPLICITY Registry. <i>Journal of Hypertension</i> , 2017 , 35, 148-153	1.9	15
218	Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPPLICITY Registry. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 833-839	2.3	9
217	Heart rate and its reduction in chronic heart failure and beyond. <i>European Journal of Heart Failure</i> , 2017 , 19, 1230-1241	12.3	24
216	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , 2017 , 389, 2226-2237	4.0	171
215	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. <i>European Heart Journal</i> , 2017 , 38, 1132-1143	9.5	109
214	True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. <i>American Heart Journal</i> , 2017 , 188, 99-108	4.9	4.0
213	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , 2017 , 70, 938-948	8.5	19
212	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017 , 19, 1361-1378	12.3	73
211	Renal Denervation for Chronic Heart Failure: Background and Pathophysiological Rationale. <i>Korean Circulation Journal</i> , 2017 , 47, 9-15	2.2	8
210	Target blood pressure in high risk cardiovascular patients. <i>Journal of Thoracic Disease</i> , 2017 , 9, E877-E878.6		
209	Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	37
208	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. <i>European Heart Journal</i> , 2017 , 38, 2671-2679	9.5	160
207	Early renin-angiotensin system inhibition induced renal deterioration may be a predictor for long-term cardiorenal outcomes. <i>Evidence-Based Medicine</i> , 2017 , 22, 185-186		
206	Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model. <i>International Journal of Cardiology</i> , 2017 , 249, 365	3.2	1
205	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017 , 136, 1374-1383	16.7	179
204	Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris. <i>Cardiology</i> , 2017 , 136, 138-144	1.6	12

203	Overestimation of cardiovascular outcome incidence - AuthorsPreply. <i>Lancet, The</i> , 2017 , 390, 2547	40	
202	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017 , 390, 2160-2170	40	406
201	Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles. <i>PLoS ONE</i> , 2017 , 12, e0176311	3.7	24
200	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPPLICITY HTN-3 and the Global SYMPPLICITY Registry. <i>European Heart Journal</i> , 2017 , 38, 93-100	9.5	79
199	Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry. <i>Clinical Research in Cardiology</i> , 2016 , 105, 873-9	6.1	55
198	Benefits of Heart Rate Slowing With Ivabradine in Patients With Systolic Heart Failure and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016 , 118, 1948-1953	3	16
197	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. <i>Journal of Hypertension</i> , 2016 , 34, 1854-62	1.9	16
196	Modulation of the sympathetic nervous system by renal denervation prevents reduction of aortic distensibility in atherosclerosis prone ApoE-deficient rats. <i>Journal of Translational Medicine</i> , 2016 , 14, 167	8.5	10
195	Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats. <i>Cardiovascular Research</i> , 2016 , 110, 371-80	9.9	27
194	Fluid status telemedicine alerts for heart failure: a randomized controlled trial. <i>European Heart Journal</i> , 2016 , 37, 3154-3163	9.5	116
193	Resting heart rate is an independent predictor of all-cause mortality in the middle aged general population. <i>Clinical Research in Cardiology</i> , 2016 , 105, 601-12	6.1	21
192	Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2016 , 105, 364-71	6.1	42
191	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016 , 171, 82-91	4.9	104
190	Renal Denervation for Chronic Heart Failure. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016 , 281-292	0.1	
189	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 1068-1075	1.9	
188	Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 1064-71	1.9	1
187	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2016 , 18, 672-83	12.3	15
186	Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 2683-93	27.4	145

185	The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study. <i>Medicine (United States)</i> , 2016 , 95, e3122	1.8	5
184	Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension: 12-month outcomes from the global SYMPLICITY registry. <i>Journal of Hypertension</i> , 2016 , 34, 2480-2486	1.9	17
183	Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	17
182	Early ivabradine treatment in patients with acute peripartum cardiomyopathy: Subanalysis of the German PPCM registry. <i>International Journal of Cardiology</i> , 2016 , 216, 165-7	3.2	25
181	Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. <i>European Heart Journal</i> , 2016 , 37, 2823-2829	9.5	93
180	Renal denervation in hypertensive patients not on blood pressure lowering drugs. <i>Clinical Research in Cardiology</i> , 2016 , 105, 755-62	6.1	17
179	Chronic exposure to ivabradine reduces readmissions in the vulnerable phase after hospitalization for worsening systolic heart failure: a post-hoc analysis of SHIFT. <i>European Journal of Heart Failure</i> , 2016 , 18, 1182-9	12.3	30
178	CardioPulse. Catheter-based renal denervation for hypertension treatment: update 2015. <i>European Heart Journal</i> , 2016 , 37, 930-3	9.5	4
177	Analyses of drugs stored at home by elderly patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2015 , 104, 320-7	6.1	19
176	First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension. <i>Hypertension</i> , 2015 , 65, 766-74	8.5	139
175	A real-world perspective on the prevalence and treatment of heart failure with a reduced ejection fraction but no specific or only mild symptoms. <i>Heart Failure Reviews</i> , 2015 , 20, 545-52	5	9
174	Reversal of Mitochondrial Transhydrogenase Causes Oxidative Stress in Heart Failure. <i>Cell Metabolism</i> , 2015 , 22, 472-84	24.6	206
173	Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy. <i>European Journal of Heart Failure</i> , 2015 , 17, 518-26	12.3	43
172	Hypertension: Arteriovenous anastomosis--next panacea for hypertension?. <i>Nature Reviews Cardiology</i> , 2015 , 12, 197-8	14.8	2
171	Catheter-based renal denervation reduces atrial nerve sprouting and complexity of atrial fibrillation in goats. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015 , 8, 466-74	6.4	49
170	Low systolic blood pressure and high resting heart rate as predictors of outcome in patients with peripartum cardiomyopathy. <i>International Journal of Cardiology</i> , 2015 , 190, 376-82	3.2	24
169	Exercise promotes collateral artery growth mediated by monocytic nitric oxide. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015 , 35, 1862-71	9.4	26
168	Heart failure with preserved ejection fraction: uncertainties and dilemmas. <i>European Journal of Heart Failure</i> , 2015 , 17, 665-71	12.3	97

167	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. <i>Clinical Research in Cardiology</i> , 2015 , 104, 1097-105	6.1	61
166	Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. <i>New England Journal of Medicine</i> , 2015 , 373, 929-38	59.2	1260
165	Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial). <i>American Journal of Cardiology</i> , 2015 , 116, 1890-7	3	48
164	Publication performance of women compared to men in German cardiology. <i>International Journal of Cardiology</i> , 2015 , 181, 267-9	3.2	6
163	Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. <i>Hypertension</i> , 2015 , 65, 193-9	8.5	84
162	Resting heart rate: risk indicator and emerging risk factor in cardiovascular disease. <i>American Journal of Medicine</i> , 2015 , 128, 219-28	2.4	109
161	Renal nerve ablation. <i>Heart</i> , 2015 , 101, 320-8	5.1	4
160	Witnessed drug intake before planned denervation--always harmless?. <i>International Journal of Cardiology</i> , 2015 , 179, 125-6	3.2	6
159	Reply: Anticoagulant-Related Nephropathy. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2682-5	5.1	0
158	Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1766-1775	15.1	126
157	Treatment of heart failure in real-world clinical practice: findings from the REFLECT-HF registry in patients with NYHA class II symptoms and a reduced ejection fraction. <i>Clinical Cardiology</i> , 2015 , 38, 200-7	3.3	13
156	Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial. <i>European Journal of Heart Failure</i> , 2015 , 17, 1294-301	12.3	51
155	Blood pressure variability after catheter-based renal sympathetic denervation in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2015 , 33, 2512-8	1.9	17
154	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. <i>Journal of Hypertension</i> , 2015 , 33, 2519-25	1.9	32
153	Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension. <i>Journal of Hypertension</i> , 2015 , 33, 1261-6	1.9	77
152	Effect of Combining Ivabradine and β -Blockers: Focus on the Use of Carvedilol in the SHIFT Population. <i>Cardiology</i> , 2015 , 131, 218-24	1.6	21
151	Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy. <i>Clinical Research in Cardiology</i> , 2015 , 104, 911-7	6.1	44
150	Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after renal sympathetic denervation. <i>Clinical Research in Cardiology</i> , 2015 , 104, 1064-71	6.1	17

149	Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure- and Heart Rate-Independent Manner. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 972-80	5	31
148	Drug therapy for the patient with resistant hypertension. <i>Future Cardiology</i> , 2015 , 11, 191-202	1.3	1
147	Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2481-93	15.1	130
146	Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. <i>Circulation</i> , 2015 , 131, 54-61	16.7	430
145	Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: the role of renal sympathetic innervation. <i>American Journal of Hypertension</i> , 2015 , 28, 256-65	2.3	45
144	A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure. <i>European Heart Journal</i> , 2015 , 36, 434-9	9.5	66
143	Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. <i>Hypertension</i> , 2015 , 65, 651-61	8.5	60
142	Pathophysiology: The Target for Renal Denervation 2015 , 1-7		1
141	Renal denervation: a novel non-pharmacological approach in heart failure. <i>Journal of Cardiovascular Translational Research</i> , 2014 , 7, 330-7	3.3	5
140	Drug adherence in patients taking oral anticoagulation therapy. <i>Clinical Research in Cardiology</i> , 2014 , 103, 173-82	6.1	41
139	Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. <i>Clinical Research in Cardiology</i> , 2014 , 103, 665-73	6.1	22
138	Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. <i>Clinical Research in Cardiology</i> , 2014 , 103, 149-59	6.1	92
137	Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). <i>American Journal of Cardiology</i> , 2014 , 113, 497-503	3	37
136	Renal denervation and heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 608-13	12.3	44
135	Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1916-23	15.1	81
134	Cardiovascular remodelling in coronary artery disease and heart failure. <i>Lancet, The</i> , 2014 , 383, 1933-43	40	469
133	Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. <i>Lancet, The</i> , 2014 , 383, 622-9	40	455
132	Atrial autonomic innervation: a target for interventional antiarrhythmic therapy?. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 215-24	15.1	97

131	Renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?. <i>Circulation Research</i> , 2014 , 115, 400-9	15.7	55
130	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve). <i>European Journal of Heart Failure</i> , 2014 , 16, 778-87	12.3	60
129	Effects of renal sympathetic denervation on exercise blood pressure, heart rate, and capacity in patients with resistant hypertension. <i>Hypertension</i> , 2014 , 63, 839-45	8.5	23
128	Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. <i>European Journal of Heart Failure</i> , 2014 , 16, 325-33	12.3	17
127	Renal denervation: effects on atrial electrophysiology and arrhythmias. <i>Clinical Research in Cardiology</i> , 2014 , 103, 765-74	6.1	32
126	Novel and nonpharmacologic approaches to cardio-protection in hypertension. <i>Current Hypertension Reports</i> , 2014 , 16, 430	4.7	5
125	Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPPLICITY HTN-2 randomized clinical trial. <i>European Heart Journal</i> , 2014 , 35, 1752-9	9.5	186
124	Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised Assessment Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. <i>Journal of Hypertension</i> , 2014 , 32, 1334-41	1.9	11
123	Effects of renal denervation on atrial arrhythmogenesis. <i>Future Cardiology</i> , 2014 , 10, 813-22	1.3	5
122	Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. <i>European Journal of Preventive Cardiology</i> , 2014 , 21, 272-80	3.9	9
121	Efficacy and safety of catheter-based radiofrequency renal denervation in stented renal arteries. <i>Circulation: Cardiovascular Interventions</i> , 2014 , 7, 813-20	6	12
120	Incidence and prevalence of pregnancy-related heart disease. <i>Cardiovascular Research</i> , 2014 , 101, 554-60	9.9	44
119	Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT. <i>European Journal of Heart Failure</i> , 2014 , 16, 810-6	12.3	51
118	Response to letter regarding article, "renal denervation for the treatment of cardiovascular high risk-hypertension or beyond?". <i>Circulation Research</i> , 2014 , 115, e19-20	15.7	
117	The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT. <i>European Journal of Heart Failure</i> , 2014 , 16, 426-34	12.3	31
116	Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial. <i>European Heart Journal</i> , 2014 , 35, 2224-31b	9.5	109
115	Association of vitamin D status and blood pressure response after renal denervation. <i>Clinical Research in Cardiology</i> , 2014 , 103, 41-7	6.1	16
114	Experimental Evidence Of The Role Of Renal Sympathetic Denervation For Treating Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2014 , 7, 1128	0.8	0

113	Catheter-based renal denervation: treating hypertension or beyond?. <i>Chinese Medical Journal</i> , 2014 , 127, 1166-8	2.9	
112	Heart rate differentiates urgency and emergency in hypertensive crisis. <i>Clinical Research in Cardiology</i> , 2013 , 102, 593-8	6.1	20
111	International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2031-45	15.1	104
110	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013 , 18, 107-22	5	39
109	Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs. <i>Heart Rhythm</i> , 2013 , 10, 1525-30	6.7	111
108	Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. <i>International Journal of Cardiology</i> , 2013 , 167, 2846-51	3.2	94
107	Effects of electrical stimulation of carotid baroreflex and renal denervation on atrial electrophysiology. <i>Journal of Cardiovascular Electrophysiology</i> , 2013 , 24, 1028-33	2.7	38
106	Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. <i>European Heart Journal</i> , 2013 , 34, 2149-57	9.5	184
105	Orthostatic function after renal sympathetic denervation in patients with resistant hypertension. <i>International Journal of Cardiology</i> , 2013 , 169, 418-24	3.2	25
104	Renal denervation in moderate treatment-resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1880-6	15.1	73
103	Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 1977-1985	15.1	90
102	Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. <i>European Journal of Heart Failure</i> , 2013 , 15, 1296-303	12.3	51
101	Risk following hospitalization in stable chronic systolic heart failure. <i>European Journal of Heart Failure</i> , 2013 , 15, 885-91	12.3	40
100	Effect of renal denervation on neurohumoral activation triggering atrial fibrillation in obstructive sleep apnea. <i>Hypertension</i> , 2013 , 62, 767-74	8.5	98
99	Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. <i>Hypertension</i> , 2013 , 61, 225-31	8.5	94
98	Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. <i>Clinical Research in Cardiology</i> , 2013 , 102, 11-22	6.1	157
97	Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. <i>American Heart Journal</i> , 2013 , 166, 306-314.e7	4.9	44
96	Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. <i>International Journal of Cardiology</i> , 2013 , 168, 2214-20	3.2	101

95	Renal sympathetic denervation: applications in hypertension and beyond. <i>Nature Reviews Cardiology</i> , 2013 , 10, 465-76	14.8	51
94	Heart rate: a global target for cardiovascular disease and therapy along the cardiovascular disease continuum. <i>Journal of Cardiology</i> , 2013 , 62, 183-7	3	39
93	Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 1125-35	27.4	248
92	2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2013 , 34, 2159-219	9.5	3400
91	Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. <i>European Heart Journal</i> , 2013 , 34, 2263-70	9.5	72
90	Heart rate and heart failure: the role of ivabradine therapy. <i>Current Opinion in Cardiology</i> , 2013 , 28, 326-31	11	6
89	2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>Journal of Hypertension</i> , 2013 , 31, 1281-357	1.9	3363
88	Renal nerve ablation reduces augmentation index in patients with resistant hypertension. <i>Journal of Hypertension</i> , 2013 , 31, 1893-900	1.9	57
87	Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2013 , 34, 2839-49	9.5	87
86	Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. <i>Circulation</i> , 2013 , 128, 132-40	16.7	199
85	Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure. <i>European Journal of Heart Failure</i> , 2013 , 15, 1044-52	12.3	19
84	Treating resistant hypertension: role of renal denervation. <i>Integrated Blood Pressure Control</i> , 2013 , 6, 119-28	3.5	9
83	Application in Hypertension of Renal Sympathetic Denervation - A Review. <i>Interventional Cardiology Review</i> , 2013 , 8, 124-126	4.2	1
82	Rationale and design of a large registry on renal denervation: the Global SYMPPLICITY registry. <i>EuroIntervention</i> , 2013 , 9, 484-92	3.1	42
81	Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation. <i>EuroIntervention</i> , 2013 , 9, 700-8	3.1	22
80	Response and non-response to renal denervation: who is the ideal candidate?. <i>EuroIntervention</i> , 2013 , 9 Suppl R, R54-7	3.1	31
79	Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure. <i>EuroIntervention</i> , 2013 , 9 Suppl R, R122-6	3.1	7
78	Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. <i>Clinical Research in Cardiology</i> , 2012 , 101, 63-7	6.1	186

77	Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1956-65	15.1	115
76	Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 901-9	15.1	396
75	Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. <i>European Heart Journal</i> , 2012 , 33, 1223-31	9.5	50
74	Hot topics in cardiology: data from IABP-SHOCK II, TRILOGY-ACS, WOEST, ALTITUDE, FAME II and more. <i>Clinical Research in Cardiology</i> , 2012 , 101, 861-74	6.1	5
73	Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. <i>Circulation</i> , 2012 , 126, 2976-82	16.7	343
72	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2012 , 14, 803-69	12.3	1892
71	Aldosterone promotes atrial fibrillation. <i>European Heart Journal</i> , 2012 , 33, 2098-108	9.5	119
70	Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). <i>Journal of the American College of Cardiology</i> , 2012 , 59, 74-83	15.1	126
69	Update on myocarditis. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 779-92	15.1	587
68	Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1938-45	15.1	183
67	Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. <i>Hypertension</i> , 2012 , 60, 419-24	8.5	245
66	The role of renal denervation in the treatment of heart failure. <i>Current Cardiology Reports</i> , 2012 , 14, 285-92	4.2	75
65	Procollagen propeptides: serum markers for atrial fibrosis?. <i>Clinical Research in Cardiology</i> , 2012 , 101, 655-61	6.1	14
64	Renal denervation in moderate to severe CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2012 , 23, 1250-7	12.7	271
63	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012 , 33, 1787-847	9.5	3691
62	Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. <i>Hypertension</i> , 2012 , 60, 172-8	8.5	179
61	Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. <i>European Heart Journal</i> , 2012 , 33, 2804-12	9.5	75
60	The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 343, 253-7	4.7	68

59	Heart rate reduction by ivabradine improves aortic compliance in apolipoprotein E-deficient mice. <i>Journal of Vascular Research</i> , 2012 , 49, 432-40	1.9	19
58	Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. <i>European Heart Journal</i> , 2012 , 33, 2813-20	9.5	97
57	Circulating microparticles as indicators of peripartum cardiomyopathy. <i>European Heart Journal</i> , 2012 , 33, 1469-79	9.5	52
56	Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1176-82	15.1	115
55	Recent advances in the treatment of hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2011 , 9, 729-44	2.5	13
54	Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. <i>Heart Rhythm</i> , 2011 , 8, 1436-43	6.7	170
53	Beneficial association of β -blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. <i>Critical Care Medicine</i> , 2011 , 39, 940-4	1.4	34
52	Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey. <i>Journal of Hypertension</i> , 2011 , 29, 1633-40	1.9	32
51	Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. <i>Journal of Hypertension</i> , 2011 , 29, 991-6	1.9	100
50	Heart rate reduction in cardiovascular disease and therapy. <i>Clinical Research in Cardiology</i> , 2011 , 100, 11-9	6.1	76
49	Sympatho-renal axis in chronic disease. <i>Clinical Research in Cardiology</i> , 2011 , 100, 1049-57	6.1	135
48	Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. <i>Circulation</i> , 2011 , 123, 1940-6	16.7	446
47	Strategies to improve drug adherence. <i>European Heart Journal</i> , 2011 , 32, 264-8	9.5	68
46	Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. <i>European Heart Journal</i> , 2011 , 32, 2034-41	9.5	245
45	Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink). <i>European Journal of Heart Failure</i> , 2011 , 13, 796-804	12.3	45
44	Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. <i>Circulation</i> , 2011 , 123, 209-15	16.7	114
43	Heart rate contributes to the vascular effects of chronic mental stress: effects on endothelial function and ischemic brain injury in mice. <i>Stroke</i> , 2011 , 42, 1742-9	6.7	60
42	Virus serology in patients with suspected myocarditis: utility or futility?. <i>European Heart Journal</i> , 2011 , 32, 897-903	9.5	124

41	Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study. <i>European Heart Journal</i> , 2011 , 32, 2395-404	9.5	141
40	Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. <i>European Heart Journal</i> , 2011 , 32, 2507-15	9.5	207
39	Elevated cytosolic Na ⁺ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. <i>Circulation</i> , 2010 , 121, 1606-13	16.7	230
38	Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). <i>European Journal of Heart Failure</i> , 2010 , 12, 75-81	12.3	72
37	From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors. <i>Cardiology</i> , 2010 , 117, 163-73	1.6	10
36	Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. <i>Circulation</i> , 2010 , 122, 900-9	16.7	271
35	Vascular pathophysiology in response to increased heart rate. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 1973-83	15.1	168
34	Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?. <i>Drugs</i> , 2010 , 70, 1215-30	12.1	33
33	Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. <i>Atherosclerosis</i> , 2010 , 212, 55-62	3.1	32
32	Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. <i>Lancet, The</i> , 2010 , 376, 886-94	40	615
31	Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. <i>Lancet, The</i> , 2010 , 376, 1903-9	40	1577
30	Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TARGET-BD). <i>British Medical Journal</i> , 2010 , 401, 1132-40	16.7	142
29	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , 2010 , 376, 875-85	40	1646
28	Atrial fibrillation and heart rate independently correlate to microalbuminuria in hypertensive patients. <i>European Heart Journal</i> , 2009 , 30, 1364-71	9.5	36
27	Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. <i>European Journal of Heart Failure</i> , 2009 , 11, 299-303	12.3	148
26	Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction. <i>Trends in Cardiovascular Medicine</i> , 2009 , 19, 152-7	6.9	26
25	Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. <i>Clinical Research in Cardiology</i> , 2009 , 98, 513-5	6.1	26
24	Physical exercise prevents cellular senescence in circulating leukocytes and in the vessel wall. <i>Circulation</i> , 2009 , 120, 2438-47	16.7	248

23	Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). <i>Journal of the American College of Cardiology</i> , 2009 , 53, 2150-8	15.1	311
22	Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. <i>European Journal of Heart Failure</i> , 2009 , 11, 631; author reply 631-2	12.3	2
21	Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. <i>Journal of Hypertension</i> , 2009 , 27, 1360-9	1.9	242
20	BEAUTIFUL results--the slower, the better?. <i>Lancet, The</i> , 2008 , 372, 779-80	40	26
19	Overview of the i-SEARCH Global Study : Cardiovascular Risk Factors and Microalbuminuria in Hypertensive Individuals. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2008 , 15, 217-24	2.9	4
18	Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. <i>Circulation</i> , 2008 , 117, 2377-87	16.7	197
17	Predictors of outcome in patients with suspected myocarditis. <i>Circulation</i> , 2008 , 118, 639-48	16.7	442
16	ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Journal of Heart Failure</i> , 2008 , 10, 93-105	12.3	1355
15	Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. <i>Journal of Hypertension</i> , 2008 , 26, 18-25	1.9	51
14	Treating to protect: current cardiovascular treatment approaches and remaining needs. <i>Medscape Journal of Medicine</i> , 2008 , 10 Suppl, S3		1
13	Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?. <i>American Journal of Cardiology</i> , 2007 , 100, 38J-44J	3	33
12	Low-grade albuminuria and cardiovascular risk : what is the evidence?. <i>Clinical Research in Cardiology</i> , 2007 , 96, 247-57	6.1	84
11	Interstitial remodeling in beta1-adrenergic receptor transgenic mice. <i>Basic Research in Cardiology</i> , 2007 , 102, 183-93	11.8	46
10	Rosuvastatin in older patients with systolic heart failure. <i>New England Journal of Medicine</i> , 2007 , 357, 2248-61	59.2	1098
9	Management of atrial fibrillation in patients with heart failure. <i>European Heart Journal</i> , 2007 , 28, 2568-73	7.5	70
8	Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. <i>Journal of Hypertension</i> , 2007 , 25, 2317-24	1.9	61
7	Does angiotensin-converting-enzyme inhibitor therapy improve cognitive function in heart failure patients?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2005 , 2, 448-9		
6	Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). <i>European Heart Journal</i> , 2005 , 26, 215-25	9.5	1076

5	Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. <i>Brain Research</i> , 2002 , 942, 23-30	3.7	245
4	Evidence for reduction of norepinephrine uptake sites in the failing human heart. <i>Journal of the American College of Cardiology</i> , 1995 , 25, 146-53	15.1	191
3	Research Output and International Cooperation Among Countries During the COVID-19 Pandemic: Scientometric Analysis (Preprint)		1
2	Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure. <i>ESC Heart Failure</i> ,	3.7	0
1	Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	1